Chargement en cours...
FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review
FLT3-mutated acute myeloid leukemia accounts for around 30% of acute myeloid leukemia (AML). The mutation carried a poor prognosis until the rise of tyrosine kinase inhibitors (TKIs). New potent and specific inhibitors have successfully altered the course of the disease, increasing the complete resp...
Enregistré dans:
| Publié dans: | Int J Mol Sci |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
MDPI
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8198781/ https://ncbi.nlm.nih.gov/pubmed/34070902 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms22115873 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|